Antifungal Susceptibility Tests and the cyp51 Mutant Strains among Clinical Aspergillus fumigatus Isolates from Korean Multicenters |
Won, Eun Jeong
(Department of Laboratory Medicine, Chonnam National University Medical School)
Joo, Min Young (Department of Laboratory Medicine, Chonnam National University Medical School) Lee, Dain (Department of Laboratory Medicine, Chonnam National University Medical School) Kim, Mi-Na (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) Park, Yeon-Joon (Department of Laboratory Medicine, The Catholic University of Korea College of Medicine) Kim, Soo Hyun (Department of Laboratory Medicine, Chonnam National University Medical School) Shin, Myung Geun (Department of Laboratory Medicine, Chonnam National University Medical School) Shin, Jong Hee (Department of Laboratory Medicine, Chonnam National University Medical School) |
1 | Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, et al. Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi. 2016;2(3):21. DOI |
2 | Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis. 2009;9(12):789-795. DOI |
3 | Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. DOI |
4 | Wiederhold NP, Gil VG, Gutierrez F, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54(1):168-171. DOI |
5 | Chen Y, Lu Z, Zhao J, et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus isolates from China. Antimicrob Agents Chemother. 2016;60(10):5878-5884. DOI |
6 | Escribano P, Recio S, Pelaez T, et al. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55(5):2460-2462. DOI |
7 | Kidd SE, Goeman E, Meis JF, et al. Multi-triazoleresistant Aspergillus fumigatus infections in Australia. Mycoses. 2015;58(6):350-355. DOI |
8 | Pham CD, Reiss E, Hagen F, et al. Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis. 2014;20(9):1498-1503. DOI |
9 | Lee HJ, Cho SY, Lee DG, et al. TR34/L98H Mutation in CYP51A Gene in Aspergillus fumigatus clinical isolates during posaconazole prophylaxis: first case in Korea. Mycopathologia. 2018;183(4):731-736. DOI |
10 | Heo MS, Shin JH, Choi MJ, et al. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea. Ann Lab Med. 2015;35(6):602-610. DOI |
11 | Snelders E, Huis In 'T Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75(12):4053-4057. DOI |
12 | CLSI. 2008. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. 2nd ed. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute. |
13 | Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol. 2016;33(2):63-75. DOI |
14 | Garcia-Rubio R, Alcazar-Fuoli L, Monteiro MC, et al. Insight into the significance of Aspergillus fumigatus cyp51A polymorphisms. Antimicrob Agents Chemother. 2018;62(6):e00241-18. |
15 | van der Linden J, Arendrup M, Warris A, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041-1044. DOI |
16 | Fraczek MG, Bromley M, Buied A, et al. The cdr1B efflux transporter is associated with noncyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2013;68(7):1486-1496. DOI |
17 | Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigates. Antimicrob Agents Chemother. 2008;52(7):2468-2472. DOI |
18 | Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54(6):2425-2430. DOI |
19 | Diaz-Guerra TM, Mellado E, Cuenca-Estrella MA, et al. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47(3):1120-1124. DOI |
20 | De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821. DOI |